Dry Eye

Sun Pharmaceutical presented Phase 4 data at ESCRS 2024 showing that cyclosporine ophthalmic solution 0.09% significantly improves dry eye disease symptoms and corneal staining in patients inadequately controlled on Restasis, with positive results observed through 12 weeks of treatment.

Study highlights safety, efficacy of device in managing persistent DED.

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to the dry eye disease treatment for millions of patients, particularly older adults.

Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team reviewed demographics, ocular histories, Standard Patient Evaluation of Eye Dryness 2 symptom survey scores, slit-lamp examinations and meibomian gland evaluations at baseline and at each visit before IPL/MGX treatments.

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

The companies’ eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago.

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025

Physicians share comprehensive approaches during roundtable discussion.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of DED.

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

TFI employs spectral interference technology to image and map the corneal surface.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

Prevent Blindness is offering educational resources and will partner with OCuSOFT Inc. in support of Dry Eye Awareness Month in July.

Alice Epitropoulos, MD, and Laura M. Periman, MD, share insights on the various diagnostic tests they employ for patients exhibiting dry eye symptoms.

Physicians wonder whether normal examination results are actually normal.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

The trial is designed to enable a resubmission of a New Drug Application to the US FDA for reproxalap after receiving a Complete Response Letter last year.

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The trial aims to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED)

According to the company, the data demonstrates sustained safety and efficacy in the treatment of the signs and symptoms in patients diagnosed with dry eye disease.

The gel is a cross-linked hyaluronic acid derivative and has been cleared by the FDA to temporarily block tear drainage by the occlusion of the canalicular system.

The launch of Blink NutriTears follows a clinical trial that demonstrated improved ocular symptom severity and tear film homeostasis, and that it helped tears stay on the eyes for 33% longer